SCHEMBL1102264

SCHEMBL1102264

CC(C(=O)Nc1ccc(S(=O)(=O)Nc2nccs2)cc1)n1ccc2cccc(F)c21

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.56
ALDH1A1 P00352 3/20 0.56
KDM4E B2RXH2 2/20 0.56
MEN1 O00255 9/20 0.56
KMT2A Q03164 9/20 0.56
SCN3A Q9NY46 2/20 0.55
SCN1A P35498 1/20 0.55
SCN4A P35499 1/20 0.55
SCN5A Q14524 1/20 0.55
SCN9A Q15858 1/20 0.55
SCN2A Q99250 1/20 0.55
SCN8A Q9UQD0 1/20 0.55
SCN10A Q9Y5Y9 1/20 0.55
POLB P06746 3/20 0.54
PKM P14618 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.52
MAPT P10636 1/20 0.50
HPGD P15428 1/20 0.50
ALOX12 P18054 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13404066 0.90 TDP1 (0.55) TDP1ALDH1A1KDM4EMEN1KMT2A
SCHEMBL1102100 0.90 MEN1 (0.56) TDP1ALDH1A1KDM4EMEN1KMT2A
SCHEMBL1102107 0.87 TDP1 (0.55) TDP1ALDH1A1KDM4EMEN1KMT2A
SCHEMBL1102265 0.86 KMT2A (0.61) TDP1ALDH1A1KDM4EMEN1KMT2A
SCHEMBL848170 0.85 ALDH1A1 (0.53) TDP1ALDH1A1KDM4EMEN1KMT2A
SCHEMBL848169 0.85 ALDH1A1 (0.53) TDP1ALDH1A1KDM4EMEN1KMT2A
SCHEMBL1102089 0.83 MEN1 (0.55) TDP1ALDH1A1KDM4EMEN1KMT2A
SCHEMBL2626055 0.83 SCN9A (0.43) TDP1ALDH1A1KDM4EMEN1KMT2A
SCHEMBL10310748 0.83 SCN9A (0.43) TDP1ALDH1A1KDM4EMEN1KMT2A
SCHEMBL1102114 0.82 KMT2A (0.61) TDP1ALDH1A1KDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153655-B2 Compositions useful as inhibitors of voltage-gated sodium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-04-10 US disclosed
US-8153655-B2 Compositions useful as inhibitors of voltage-gated sodium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-04-10 US disclosed
US-20100087479-A1 Compositions Useful as Inhibitors of Voltage-Gated Sodium Channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-04-08 US disclosed
US-20100087479-A1 Compositions Useful as Inhibitors of Voltage-Gated Sodium Channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-04-08 US disclosed
US-7615563-B2 Compositions useful as inhibitors of voltage-gated sodium channels VERTEX PHARMACEUTICALS INCORPORATED 2009-11-10 US disclosed
US-7615563-B2 Compositions useful as inhibitors of voltage-gated sodium channels VERTEX PHARMACEUTICALS INCORPORATED 2009-11-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087479-A1 Compositions Useful as Inhibitors of Voltage-Gated Sodium Channels SCNN1G, KCNN3, KCNN2 TDP1 2356/4885ALDH1A1 2811/4885KDM4E 2385/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.